251 related articles for article (PubMed ID: 22824628)
1. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.
Dash PK; Gendelman HE; Roy U; Balkundi S; Alnouti Y; Mosley RL; Gelbard HA; McMillan J; Gorantla S; Poluektova LY
AIDS; 2012 Nov; 26(17):2135-44. PubMed ID: 22824628
[TBL] [Abstract][Full Text] [Related]
2. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.
Kanmogne GD; Singh S; Roy U; Liu X; McMillan J; Gorantla S; Balkundi S; Smith N; Alnouti Y; Gautam N; Zhou Y; Poluektova L; Kabanov A; Bronich T; Gendelman HE
Int J Nanomedicine; 2012; 7():2373-88. PubMed ID: 22661891
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.
Puligujja P; Balkundi SS; Kendrick LM; Baldridge HM; Hilaire JR; Bade AN; Dash PK; Zhang G; Poluektova LY; Gorantla S; Liu XM; Ying T; Feng Y; Wang Y; Dimitrov DS; McMillan JM; Gendelman HE
Biomaterials; 2015 Feb; 41():141-50. PubMed ID: 25522973
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.
Gautam N; Roy U; Balkundi S; Puligujja P; Guo D; Smith N; Liu XM; Lamberty B; Morsey B; Fox HS; McMillan J; Gendelman HE; Alnouti Y
Antimicrob Agents Chemother; 2013 Jul; 57(7):3110-20. PubMed ID: 23612193
[TBL] [Abstract][Full Text] [Related]
5. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections.
Puligujja P; McMillan J; Kendrick L; Li T; Balkundi S; Smith N; Veerubhotla RS; Edagwa BJ; Kabanov AV; Bronich T; Gendelman HE; Liu XM
Nanomedicine; 2013 Nov; 9(8):1263-73. PubMed ID: 23680933
[TBL] [Abstract][Full Text] [Related]
6. Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.
Guo D; Zhang G; Wysocki TA; Wysocki BJ; Gelbard HA; Liu XM; McMillan JM; Gendelman HE
J Virol; 2014 Sep; 88(17):9504-13. PubMed ID: 24920821
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.
Gautam N; Puligujja P; Balkundi S; Thakare R; Liu XM; Fox HS; McMillan J; Gendelman HE; Alnouti Y
Antimicrob Agents Chemother; 2014 Dec; 58(12):7510-9. PubMed ID: 25288084
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice.
Puligujja P; Araínga M; Dash P; Palandri D; Mosley RL; Gorantla S; Poluektova L; McMillan J; Gendelman HE
Antiviral Res; 2015 Aug; 120():85-8. PubMed ID: 26026666
[TBL] [Abstract][Full Text] [Related]
9. Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.
Martinez-Skinner AL; Veerubhotla RS; Liu H; Xiong H; Yu F; McMillan JM; Gendelman HE
J Proteome Res; 2013 May; 12(5):2282-94. PubMed ID: 23544708
[TBL] [Abstract][Full Text] [Related]
10. The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.
Zhang G; Guo D; Dash PK; Araínga M; Wiederin JL; Haverland NA; Knibbe-Hollinger J; Martinez-Skinner A; Ciborowski P; Goodfellow VS; Wysocki TA; Wysocki BJ; Poluektova LY; Liu XM; McMillan JM; Gorantla S; Gelbard HA; Gendelman HE
Nanomedicine; 2016 Jan; 12(1):109-22. PubMed ID: 26472049
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.
Roy U; McMillan J; Alnouti Y; Gautum N; Smith N; Balkundi S; Dash P; Gorantla S; Martinez-Skinner A; Meza J; Kanmogne G; Swindells S; Cohen SM; Mosley RL; Poluektova L; Gendelman HE
J Infect Dis; 2012 Nov; 206(10):1577-88. PubMed ID: 22811299
[TBL] [Abstract][Full Text] [Related]
12. Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages.
Araínga M; Guo D; Wiederin J; Ciborowski P; McMillan J; Gendelman HE
Retrovirology; 2015 Jan; 12():5. PubMed ID: 25608975
[TBL] [Abstract][Full Text] [Related]
13. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.
Nowacek AS; McMillan J; Miller R; Anderson A; Rabinow B; Gendelman HE
J Neuroimmune Pharmacol; 2010 Dec; 5(4):592-601. PubMed ID: 20237859
[TBL] [Abstract][Full Text] [Related]
14. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.
Nowacek AS; Balkundi S; McMillan J; Roy U; Martinez-Skinner A; Mosley RL; Kanmogne G; Kabanov AV; Bronich T; Gendelman HE
J Control Release; 2011 Mar; 150(2):204-11. PubMed ID: 21108978
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Active HIV-1 Infection in CD34
Latinovic OS; Neal LM; Tagaya Y; Heredia A; Medina-Moreno S; Zapata JC; Reitz M; Bryant J; Redfield RR
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):718-728. PubMed ID: 31099257
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
[TBL] [Abstract][Full Text] [Related]
17. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
[TBL] [Abstract][Full Text] [Related]
18. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
Sevinsky H; Zaru L; Wang R; Xu X; Pikora C; Correll TA; Eley T
Pediatr Infect Dis J; 2018 Jun; 37(6):e157-e165. PubMed ID: 29206748
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
